glucose, (beta-d)-isomer has been researched along with Acidosis, Diabetic in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 36 (62.07) | 24.3611 |
2020's | 22 (37.93) | 2.80 |
Authors | Studies |
---|---|
Kainz, M; Schiferer, A; Tschernko, E; Wohlrab, P; Zapletal, B | 1 |
Abu Shamsi, MY; Ismail, I; Kamaruddin, NA; Sukor, N; Wan Azman, SS | 1 |
Chepulis, L; Paul, R; Yu, A | 1 |
Bardhi, O; Bloom, MD; Sattari, M | 1 |
Aktas, G; Bilgin, S; Duman, TT; Kurtkulagi, O; Yilmaz, F | 1 |
Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D | 1 |
Alduraibi, RK; Alrebdi, YM; Altowayan, YF | 1 |
Cowen, J; Leader, R; Rajeev, SP | 1 |
Asada, K; Ide, N; Ito, M; Kitajima, S; Matsushima, S; Obayashi, M; Yamamoto, M | 1 |
Cho, H; Park, JH; Seo, I; Shim, HM | 1 |
Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
Fourlanos, S; Neoh, SL; Nolan, BJ; Varadarajan, S | 1 |
Alper, E; Deyneli, O; Esin, A; Meriçöz, Ç; Sezer, H; Yazıcı, D | 1 |
Ahn, DJ; Lee, IH | 1 |
Gastelum, AA; Latif, A; Reddy, JT; Sood, A | 1 |
Bantis, K; Daikidou, D; Dimitriadis, C; Kasimatis, E; Papagianni, A; Papanikolaou, A; Sampani, E; Sarafidis, P | 1 |
Akamizu, T; Ariyasu, H; Furukawa, Y; Furuta, H; Inaba, H; Iwakura, H; Kishimoto, S; Kitahara, C; Matsuno, S; Morita, S; Nishi, M; Takeshima, K; Uraki, S | 1 |
Chen, R; Li, N; Liu, K | 1 |
Ozer, O; Yorulmaz, G | 1 |
Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
Dashora, U; Dhatariya, K; Gregory, R; Macklin, A; Nagi, D; Patel, DC; Rayman, G; Rowles, S; Winocour, P | 1 |
Chadha, S; Jayasinghe, R; Niranjan, S; Oldfield, K | 1 |
Milanes, L; Voskertchian, A | 1 |
Bourron, O; Hartemann, A; Jeannin, AC; Laroche, S; Phan, F | 1 |
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
Aschenbrenner, DS | 1 |
Ahmed, M; Crowley, RK; McKenna, MJ | 1 |
Greenfield, JR; Isaacs, M; Tonks, KT | 1 |
Pereyra A, M; Ramírez, C; Román, R | 1 |
Bailey, CJ; Jabbour, S; Karup, C; Langkilde, AM; Scheen, A; Seufert, J | 1 |
Brown, F; McColl, T | 1 |
Dull, RB; Knezevich, EL; Lau, BM; Spangler, ML | 1 |
Lin, YH | 1 |
Bain, SC; Bashir, J; Chudleigh, R; Nalla, P; Peter, R | 1 |
Akturk, HK; Garg, SK; Rewers, A | 1 |
Ebenbichler, CF; Kempf, P; Laimer, M; Lunger, L; Mader, JK; Melmer, A; Pieber, TR; Stettler, C; Tilg, H | 1 |
Chou, YM; Goh, ZNL; Lin, CC; Seak, CJ; Seak, CK; Seak, JC | 1 |
Acosta-Delgado, D; Hernandez-Quiles, C; Ramirez-Duque, N | 1 |
Athyros, V; Doumas, M; Imprialos, K; Patoulias, D; Stavropoulos, K | 1 |
Henry, RR; McCrimmon, RJ | 1 |
Inzucchi, SE; Lupsa, BC | 1 |
Akyol, PY; Karakaya, Z; Payza, U; Topal, F; Topal, FE | 1 |
Abdul-Ghani, M; DeFronzo, RA; Fawaz, M; Jayyousi, A; Megahed, A; Migahid, O; Singh, R | 1 |
Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P | 1 |
Donnan, K; Segar, L | 1 |
Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
Boeder, S; Edelman, SV | 1 |
Gilbert, JD; Goldenberg, RM; Hramiak, IM; Woo, VC; Zinman, B | 1 |
Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB; Peters, AL | 1 |
Blau, JE; Rother, KI; Taylor, SI | 1 |
Bagger, JI; Knop, FK; Rungby, J; Storgaard, H; Vilsbøll, T | 1 |
Bloomgarden, ZT | 1 |
Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
Valek, R; Von der Mark, J | 1 |
Hou, SK; Kao, WF; Li, SJ; Wang, AY | 1 |
Kristensen, FB; Lindberg, MJ; Yildiz, A | 1 |
Ejskjaer, N; Heinemann, L; Klonoff, D; Pfützner, A; Pickup, J | 1 |
15 review(s) available for glucose, (beta-d)-isomer and Acidosis, Diabetic
Article | Year |
---|---|
A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Network Meta-Analysis | 2022 |
Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Topics: Acid-Base Equilibrium; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Gas Analysis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycerophosphates; Humans; Hypoglycemic Agents; Hysterectomy; Insulin; Middle Aged; Postoperative Complications; Sodium Bicarbonate; Sodium-Glucose Transporter 2 Inhibitors; Surgical Wound Infection | 2020 |
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Topics: Adult; Aged; Amputation, Surgical; Benzhydryl Compounds; Blood Volume; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Double-Blind Method; Female; Fractures, Spontaneous; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections | 2018 |
Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Treatment Outcome | 2018 |
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT inhibitor adjunct therapy in type 1 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemic Agents; International Cooperation; Multicenter Studies as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1 | 2018 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SGLT2 Inhibitors May Predispose to Ketoacidosis.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Susceptibility; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
4 trial(s) available for glucose, (beta-d)-isomer and Acidosis, Diabetic
Article | Year |
---|---|
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Administration Schedule; Glucosides; Humans; Insulin Resistance; Ketone Bodies; Male; Middle Aged; Pilot Projects; Postprandial Period | 2018 |
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Exenatide; Female; Glucosides; Humans; Insulin; Ketones; Male; Middle Aged; Pioglitazone; Qatar; Treatment Outcome | 2019 |
39 other study(ies) available for glucose, (beta-d)-isomer and Acidosis, Diabetic
Article | Year |
---|---|
Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiac Surgical Procedures; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans | 2022 |
Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Ketoacidosis; Glucose; Glucosides; Glycemic Control; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The incidence of diabetic ketoacidosis associated with empagliflozin use in Aotearoa New Zealand: a preliminary review.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Ketoacidosis; Glucosides; Humans; Incidence; New Zealand | 2022 |
Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Male; Pancreatitis; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucose; Glucosides; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2023 |
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hyperglycemia; Kidney Tubules, Proximal; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
[Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Topics: Benzhydryl Compounds; Diabetic Ketoacidosis; Diet, Carbohydrate-Restricted; Glucose; Glucosides; Humans; Insulin; Isotonic Solutions; Male; Middle Aged; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Lipolysis; Male; Melatonin; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
Topics: Aged; Autoantibodies; Benzhydryl Compounds; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketosis; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment | 2020 |
Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin).
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Diet, Ketogenic; Female; Fluid Therapy; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Time-to-Treatment | 2020 |
Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Intraoperative Complications; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thoracic Surgical Procedures | 2021 |
Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
Topics: Adult; Benzhydryl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Female; Glucosides; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Overweight; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2021 |
Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions.
Topics: Aged; Benzhydryl Compounds; Brain Neoplasms; Coronary Angiography; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Echocardiography; Glucosides; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Nivolumab; Sodium-Glucose Transporter 2 Inhibitors; Takotsubo Cardiomyopathy | 2021 |
Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetic Ketoacidosis; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans | 2021 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes Drug Receives New Indication.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Labeling; Drug Repositioning; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Education as Topic; Patient Selection; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
Topics: Adolescent; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin | 2017 |
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.
Topics: Abdominal Pain; Anorexia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2; Vomiting | 2018 |
Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Infections; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors.
Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2018 |
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
Topics: Abdominal Pain; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dyspnea; Fatigue; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Nausea; Vomiting | 2018 |
Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Coma; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Pancreatitis; Propensity Score; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Urinary Tract Infections; Venous Thromboembolism | 2018 |
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney Tubules, Proximal; Male; Medication Therapy Management; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Gliflozins: ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents | 2016 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
[Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2017 |